ByteDance has launched a carve-out and independent financing process for its AI drug unit while retaining a controlling stake. The new entity will take the unit's core team, AI4S algorithms, technology platform and existing pipeline assets and will continue to receive compute from Volcano Engine. The unit, founded in 2021 and led by Liu Kai, comprises about 50 core members of AI4S algorithm engineers and senior pharmaceutical experts. The team has handled work from foundational model research th

ByteDance has launched a carve-out and independent financing process for its AI drug unit while retaining a controlling stake. The new entity will take the unit's core team, AI4S algorithms, technology platform and existing pipeline assets and will continue to receive compute from Volcano Engine. The unit, founded in 2021 and led by Liu Kai, comprises about 50 core members of AI4S algorithm engineers and senior pharmaceutical experts. The team has handled work from foundational model research through industrialization.